Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development Genialis, the RNA biomarker company, today announced an ...

Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.

BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a ...

New University of Virginia School of Medicine research revealing the fingerprints of Sudden Infant Death Syndrome (SIDS) ...

Proteome Sciences plc (LON:PRM – Get Free Report)’s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 3.35 ($0.04) and ...

By studying biomarkers known to be involved in gastrointestinal cancers, researchers at the Johns Hopkins Kimmel Cancer ...

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...

PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to ...

Tiziana Life Sciences announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) who were treated with intranasal foralumab ...

Tiziana Life Sciences, Ltd., a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal ...